Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 10/20 | 0.46 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286878 | 0.94 | SPHK1 (0.43) | SPHK1HAO1SPHK2EPHX1EPHX2 | |
| SCHEMBL4291335 | 0.91 | S1PR1 (0.49) | SPHK1HAO1SPHK2EPHX1EPHX2 | |
| SCHEMBL4296068 | 0.88 | SPHK1 (0.43) | SPHK1HAO1SPHK2EPHX1EPHX2 | |
| SCHEMBL4297651 | 0.85 | SPHK1 (0.49) | SPHK1HAO1EPHX1EPHX2THRA | |
| SCHEMBL4288639 | 0.82 | S1PR1 (0.48) | SPHK1SPHK2EPHX1EPHX2S1PR1 | |
| SCHEMBL4295767 | 0.82 | S1PR1 (0.48) | SPHK1SPHK2EPHX1EPHX2S1PR1 | |
| SCHEMBL13659721 | 0.82 | S1PR1 (0.48) | SPHK1SPHK2EPHX1EPHX2S1PR1 | |
| SCHEMBL5795055 | 0.80 | SPHK1 (0.37) | SPHK1HAO1SPHK2EPHX1EPHX2 | |
| SCHEMBL4288723 | 0.80 | THRA (0.42) | SPHK1SPHK2THRATHRBS1PR1 | |
| SCHEMBL4298741 | 0.79 | CNR2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| WO-2006043149-A9 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET SOC CIV (FR) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006043149-A2 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET (FR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | SPHK1 7/4885HAO1 2409/4885SPHK2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.